Articles

Kurta Law is investigating potentially unsuitable broker recommendations of Rosetta Genomics. It belongs to a group of more than 180 stocks underwritten by Aegis Capital […]

Kurta Law is investigating broker recommendations of Ritter Pharmaceuticals (RTTR). The company disclosed significant risks in its prospectus that brokerage firms should have disclosed to […]

Kurta Law is investigating investor losses on shares of RiT Technologies stock. The company discloses the substantial risks involved in its stock in its prospectus, […]

Kurta Law is investigating recommendations of Rennova Health (RNVA) stock for their potential unsuitability for investors. Brokers have a duty to recommend investments that are […]

Kurta Law is investigating broker recommendations of RedHill Biopharma (RDHL). The risks associated with this stock were clearly disclosed in the company’s prospectus. Brokers who […]

Kurta Law is investigating potentially unsuitable recommendations of PURE BioScience stock to investors. In its prospectus, a disclosure filed with the SEC, the company described […]

Kurta Law is investigating potentially unsuitable recommendations of Precipio stock to investors. When companies conduct a stock offering, they must file a type of disclosure […]

Kurta Law is investigating recommendations of ParaZero Technologies (PRZO) stock for their possible unsuitability for investors. Brokers have an obligation to recommend investments that match […]

Kurta Law is investigating broker recommendations of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). These investments were high-risk, making them unsuitable for many investors. Unsuitable investments violate […]

Kurta Law is investigating broker recommendations of Opexa Therapeutics (NASDAQ: OPXA). Opexa Therapeutics investments came with a high degree of risk, making them unsuitable for […]